The FDA released a much-anticipated draft guidance on how makers of rare disease genetic medicines can leverage a platform ...

Researchers are evaluating the P-CARE model, which integrates results from a blended genome-exome sequencing assay and family ...

The FDA cleared a second arm for enrollment in the trial after one NSCLC patient demonstrated a complete response to the non-boosted therapy.

NEW YORK – CAR T-cell therapies have been on the market for nearly a decade, but researchers are still working to understand why some patients develop side effects like cytokine release syndrome or ...

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.

The recommendation is based on results from 77 patients with pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation.

GSK will pay the Chinese company $40 million upfront and up to $963 million in payments linked to development, regulatory, and commercial milestones.

In a study with three UK academic institutions, the platform agreed with MDx results 94 percent of the time in detecting ...

The gene therapy, which was acquired by Novartis in 2023, is also being tested in a separate Phase I/II trial of pediatric ...

NEW YORK – Iovance Biotherapeutics will begin a registrational trial of its autologous tumor infiltrating lymphocyte (TIL) therapy Amtagvi (lifileucel) in previously treated patients with advanced ...

Beam also unveiled a new platform-based approach to phenylketonuria treatments and a $500 million senior secured credit facility.